The report of the joint committee between the Audit Bureau and the Anti-Corruption Authority revealed that the financial trajectory of the Medical Supply Organization during the period 2022–2025 is non-linear and reflects the absence of a stable pharmaceutical demand model.
The report stated that the sharp change in expenditure does not correspond to the nature of the healthcare sector, which is expected to demonstrate stability or gradual growth. This indicates weaknesses in financial planning and the absence of a link between allocated budgets and actual consumption indicators.
According to the report, the sharp discrepancy in funding for certain specialized authorities reflects a lack of stability in financing policies. The Cancer Control Authority recorded a decline from 1.56 billion in 2024 to 12 million in 2025.
It also noted that the institutional expansion in the number of beneficiary entities led to clear regulatory inflation, as the system shifted from a clearly centralized structure in 2022 to more than 25 entities in 2025, resulting in reduced traceability and increased risks of corruption.
The report further confirmed that the assessment of financial efficiency reveals structural weaknesses in the financial governance of pharmaceuticals, manifested in the absence of centralized procurement, weak tracking mechanisms, and fluctuating expenditure, all of which increase the likelihood of waste and misuse.
